Aclaris Therapeutics, Inc. (ACRS)

3.49 +0.11 (+3.25%) USD  |  NASDAQ  |  Oct 15, 16:00
3.46 -0.03 (-0.86%) After-Hours: 05:54
More

Aclaris Therapeutics Research and Development Expense (Quarterly) : 18.07M for June 30, 2026

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 18.07M
March 31, 2026 15.66M
December 31, 2025 16.58M
September 30, 2025 13.03M
June 30, 2025 11.45M
March 31, 2025 11.58M
December 31, 2024 9.026M
September 30, 2024 5.956M
June 30, 2024 8.759M
March 31, 2024 9.845M
December 31, 2023 26.65M
September 30, 2023 23.88M
June 30, 2023 25.28M
March 31, 2023 22.59M
December 31, 2022 21.07M
September 30, 2022 23.66M
June 30, 2022 18.78M
March 31, 2022 14.31M
December 31, 2021 14.10M
September 30, 2021 13.98M
June 30, 2021 7.897M
March 31, 2021 7.838M
Date Value
December 31, 2020 8.956M
September 30, 2020 6.24M
June 30, 2020 6.466M
March 31, 2020 7.677M
December 31, 2019 11.46M
September 30, 2019 16.18M
June 30, 2019 16.78M
March 31, 2019 19.64M
December 31, 2018 18.62M
September 30, 2018 15.19M
June 30, 2018 13.98M
March 31, 2018 13.61M
December 31, 2017 13.19M
September 30, 2017 10.86M
June 30, 2017 7.965M
March 31, 2017 7.772M
December 31, 2016 6.943M
September 30, 2016 7.123M
June 30, 2016 9.797M
March 31, 2016 9.495M
December 31, 2015 2.113M
September 30, 2015 9.408M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Corcept Therapeutics, Inc. 53.89M
Alumis, Inc. 84.46M
ANI Pharmaceuticals, Inc. 14.75M
Veru, Inc. 4.353M
Johnson & Johnson 4.652B